

2021-2022 Synagis Seasonal Respiratory Syncytial Virus Enrollment Form



Fax Referral To: 1-800-323-2445

Email Referral To: Customer.ServiceFax@CVSHealth.com

Phone: 1-800-237-2767

Six Simple Steps to Submitting a Referral

1 PATIENT INFORMATION *(Complete or include demographic sheet)*

Patient Name: _____ Address: _____ City, State, ZIP Code: _____

Preferred Contact Methods:

Phone (to primary # provided below) Text (to cell # provided below) Email (to email provided below)

Note: Carrier charges may apply. If unable to contact via text or email, Specialty Pharmacy will attempt to contact by phone.

Primary Phone: _____ Alternate Phone: _____ DOB: _____ Gender: Male Female

Email: _____ Last Four of SSN: _____ Primary Language: _____

2 PRESCRIBER INFORMATION

Prescriber's Name: _____ State License #: _____

NPI #: _____ DEA #: _____ Group or Hospital: _____

Address: _____ City, State, ZIP Code: _____

Phone: _____ Fax: _____ Contact Person: _____ Contact's Phone: _____

3 INSURANCE INFORMATION Please fax copy of prescription and insurance cards with this form, if available (front and back)

Prescription Card:

Name of Insurer: _____ ID#: _____ BIN: _____ PCN: _____ Group: _____

Medical Insurance:

Subscriber: _____ ID#: _____ Name of Insurer: _____ Phone: _____

Secondary Insurance:

Subscriber: _____ ID#: _____ Name of Insurer: _____ Phone: _____

4 DIAGNOSIS AND CLINICAL INFORMATION

Needs by Date: _____ Expected date of first injection: _____ Ship to: Patient Office Other: _____

Diagnosis (ICD-10):

Gestational Age: < 23 wks (P07.21) 23 wks (P07.22) 24 wks (P07.23) 25 wks (P07.24)
 26 wks (P07.25) 27 wks (P07.26) 28 wks (P07.31) 29 wks (P07.32)
 30 wks (P07.33) 31 wks (P07.34) 32 wks (P07.35) 33 wks (P07.36)
 34 wks (P07.37) 35 wks (P07.38)

Nursing:

No nursing coordination Yes, CVS Specialty to coordinate home health nurse visit for injection

Chronic Respiratory Disease Arising in the Perinatal Period:

Wilson-Mikity Syndrome (P27.0)
 Bronchopulmonary Dysplasia originating in the perinatal period (P27.1)
 Other chronic respiratory disease originating in the perinatal period (P27.8)

Congenital Abnormality of Respiratory System:

Congenital Subglottic Stenosis (Q31.1) Other Congenital Malformations of Trachea (Q32.1)
 Laryngocele (Q31.3) Other Congenital Malformations of Bronchus (Q32.4)
 Other Congenital Malformations of Larynx (Q31.8) Congenital Cystic Lung (Q33.0)

2021-2022 Synagis Seasonal Respiratory Syncytial Virus Enrollment Form

Please complete Patient and Prescriber information

Patient Name: _____ Patient DOB: _____
 Prescriber Name: _____ Prescriber Phone: _____

4 DIAGNOSIS AND CLINICAL INFORMATION continued

Patient's Gestational Age (required): _____ weeks _____ days Patient's Birth Weight: _____ g / kg / lbs (please circle)
 Current Weight: _____ g / kg / lbs (please circle) Date Recorded: ____/____/____
 Did patient receive Synagis last season? No Yes Dates of Synagis doses given this season: _____
 Multiple births: No Yes Enter names of Synagis candidates (submit separate enrollment forms): _____
 Daycare attendance: No Yes School-age siblings in home: No Yes
 NICU history: No Yes If yes, NICU name and include NICU summary: _____
 Allergies: _____ Medical conditions not listed below: _____

Clinical Conditions: 2014 AAP Committee on Infectious Disease and Bronchiolitis Guidelines

Chronic Lung Disease (CLD):

< 12 months of age with CLD*
 < 24 months of age with CLD* AND continues to require medical support during the 6-month period before second RSV season
 AND Supplemental oxygen (dates) _____ Chronic corticosteroids (drugs/dates) _____
 Diuretic therapy (drugs/dates) _____ Bronchodilators (drugs/dates) _____

*CLD of prematurely defined as gestational age < 31 weeks, 6 days AND requirement for 21% oxygen for at least the first 28 days after birth

Congenital Heart Disease (CHD):

< 12 months of age at start of season with hemodynamically significant CHD such as:
 Acyanotic heart disease and receiving medication to control congestive heart failure and surgery to correct (meds/dates) _____ (surgery date) _____
 Moderate to severe pulmonary hypertension
 Other: describe _____
 < 24 months of age undergoing cardiac transplantation during the RSV season (date) _____
 Cyanotic Heart Disease: diagnosis _____

Airway/Neuro-muscular Conditions:

< 12 months of age at start of season and compromised handling of secretions AND due to
 Significant abnormality of the airway (attach clinical notes) Neuromuscular condition (attach clinical notes)

Prematurity: < GA 28 wks, 6 days AND < 12 months at start of season

Other conditions: Other medical history (describe) _____

5 PRESCRIPTION INFORMATION

MEDICATION	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
<input type="checkbox"/> Synagis (palivizumab)	50 mg and/or 100 mg vials	<input type="checkbox"/> Inject 15 mg/kg IM one time per month <input type="checkbox"/> Other: _____	Quantity: QS to achieve 15 mg/kg dose Refills: _____
<input type="checkbox"/> Epinephrine	1:1000 amp	Inject 0.01 mg/kg SC as directed for anaphylaxis	Quantity: _____ Refills: 0

Patient is interested in patient support programs

STAMP SIGNATURE NOT ALLOWED

Ancillary supplies and kits provided as needed for administration

6 PHYSICIAN SIGNATURE REQUIRED

PRODUCT SUBSTITUTION PERMITTED

(Date)

DISPENSE AS WRITTEN

(Date)

X _____

X _____

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.